Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This review concerns the clinical impact of treating hyperlipidemia. The U.S. Lipid Research Clinics Coronary Primary Prevention Trial, the Helsinki Heart Study, and the Oslo Primary Prevention Trial all consistently showed that intensive and long-term (5-7 years) lipid-lowering treatment is successful in reducing the incidence of fatal and nonfatal myocardial infarction. Secondary prevention trials (Coronary Drug Project and the Stockholm Ischaemic Heart Disease Secondary Prevention Study) have overall confirmed this result. Assessment of progression/regression of atherosclerosis by invasive or noninvasive methods has shown that an important mechanism underlying the reduction of coronary events with long-term lipid-lowering treatment is that involving stabilization or regression of arterial lesions. An additional advantage from lipid-lowering treatment might come from useful hemodynamic changes, occurring shortly after the start of an intensive cholesterol-lowering treatment with low-density lipoprotein apheresis.
 ...
PMID:Clinical relevance of hyperlipidemia. 227 73

Between 1974 and 1988, 7 myocardial infarctions occurred in 6 (4 men, 2 women) out of 400 systemic lupus erythematosus patients. Their ages at the onset of lupus ranged from 13 to 44 years (m = 26). Four had renal involvement. Control of lupus in all 6 patients required high-dose steroids (at least 1 mg/kg/d of prednisone). Myocardial infarction occurred 4 to 19 years after the onset of lupus (m = 13). One patient died of cardiogenic shock. When the infarction occurred, only one patient was undergoing a lupus flare, while the disease was quiescent or slightly active in the 5 others. One patient had no risk factors for atheroma but had been taking steroids for 10 years. Among the other 4, one had hypertension, another had hyperlipidemia and 3 were smokers; they had been on steroids for 2, 4, 11 and 13 years. Coronary angiogram showed occlusion in all 4, but atheroma in only 2 patients. Lupus anticoagulant was present in 3 of these 4 patients. The mechanisms responsible for coronary occlusion in lupus patients are probably complex and interwoven. In addition to "classical" factors (i.e., vasculitis or steroid-induced atheroma), other factors, such as antiphospholipid antibodies and/or smoking, may play an important thrombogenic role.
 ...
PMID:[Myocardial infarction in systemic lupus erythematosus. 7 cases in 6 patients]. 228 5

The overall risk of oral contraceptive (OC) use is minimal when women over 35 years of age, smokers, and those with multiple risk factors (thromboembolic disorders, cerebrovascular or coronary artery disease, liver tumors, breast cancer, estrogen-dependent neoplasms, undiagnosed abnormal genital bleeding, and congenital hyperlipidemia) are excluded. OC use increases the risk of hypertension by 1-5%, depending on age, parity, and duration of use, but even this small risk is decreased when multiphasic OCs are prescribed. Deep venous thrombosis in the leg is 4 times more prevalent in OC users than nonusers and the risk of superficial thrombosis is doubled. Again, fewer thromboembolic complications occur when the estrogen dosage is low. The risk of myocardial infarction is not believed to increase with OC use as long as other risk factors--smoking, obesity, hypertension, age over 35 years, hypercholesterolemia--are not present. Studies involving the original high-dose OCs revealed a 3-fold increase in the risk of thrombotic stroke and a 2-fold increase in the risk of hemorrhagic stroke, but low-dose OCs appear to have no effect on the potential for stroke. The impact of OC use on breast cancer cannot yet be determined given the very long latency period of this cancer. In terms of benign breast disease, OC users have been shown to be at substantially reduced risk of lesions, fibroadenomas, and fibrocystic changes. OCs also protect women from endometrial and ovarian cancer, although the pill seems to accelerate the progression of cervical dysplasia. Other beneficial effects of OC use include reductions in the incidence of pelvic inflammatory disease, endometriosis, ectopic pregnancy, and ovarian cysts.
 ...
PMID:Oral contraceptive pills. Part II: Potential complications and health benefits. 228 19

Hyperlipidaemia has become generally accepted as a cause of coronary artery atherosclerosis, arterial occlusion and subsequent myocardial infarction. This may be true in a few people with lipid intolerance, but for the majority, hyperlipidaemia represents a normal physiological response to another pathological process. One such disease process involves the vessel wall, which appears to suffer injury. The cause of the injury may be associated with abnormal movement in the wall and this in turn can be provoked by stress. A hypothesis encompassing these observations is proposed. It would therefore appear that hyperlipidaemia is not a cause of arterial disease, but as part of normal homeostasis, it can be a risk indicator. It is dangerous to consider hyperlipidaemia as a cause of myocardial infarction as this leads to inappropriate treatment. The lowering of cholesterol and low density lipoproteins (LDL) by any means other than sensible dieting may be likened to attempts to lower elevated white blood cell counts in cases of bacterial pneumonia, without treating the pneumonia.
 ...
PMID:Hyperlipidaemia and atherogenesis. 229 87

Elevated blood cholesterol levels, a major risk for coronary artery disease in adults, has been associated with atherosclerotic disease in children. More than 10% of North American children have blood cholesterol levels higher than the desirable levels for adults. Current guidelines recommend screening only in children who have a family history of hyperlipidemia or myocardial infarction at an early age; however, this method fails to identify most children with hypercholesterolemia. Office-based cholesterol screening is an effective means to identify children and family members for dietary assessment and counseling. Should these measures be insufficient to lower the child's cholesterol level, referral for pharmacologic treatment is indicated.
 ...
PMID:Cholesterol screening in children during office visits. 229 54

Despite of certain successes from preventive measures, myocardial infarction and coronary heart disease are still responsible for a great part of deaths and premature disabilities in western industrialized nations. The rates are even increasing in Eastern Europe. In the Far East, however, incidence of myocardial infarction is low due to nutrition habits low in fat and low serum cholesterol levels. In 1986 and 1988 European Consensus Conferences have agreed on recommendations for the prevention of coronary heart disease. The population strategy seeks to improve the health-oriented behaviour of the whole population. The goal of the individual or high risk strategy is the identification and treatment of persons who are at particular risk. Among the influenceable risk factors hyperlipidemia, hypertension and cigarette smoking are of decisive importance. It is a goal to reduce cholesterol levels to 200 mg/dl by means of lipid lowering diet and, if necessary, drug treatment.
 ...
PMID:[The European cholesterol concensus conferences. Do coronary heart diseases still play a major role in our society?]. 233 67

Sixty-five cases were evaluated for silent myocardial ischaemia (SMI) by computerised treadmill test (TMT) and ambulatory electrocardiographic monitoring (AEM). There were 59 males and 6 females. The cases were divided into GP-I-stable angina (35 cases) GP-II-stable angina after myocardial infarction (15 cases) and GP-III-asymptomatic (15 cases). Age in each group ranged from 36 years to 62 years (GP-I), 40 years to 68 years (GP-II) and 36 years to 48 years (GP-III). Conventional risk factors viz. hypertension, diabetes mellitus, hyperlipidemia, smoking and family history were assessed with a view to see their implication on SMI. 43 patients (62.2%) were found to have SMI including mixed episodes. Out of these 43, TMT was positive in 29 patients (67.4%), AEM was positive in 41 patients (95.3%) and both TMT and AEM were positive in 27 patients (62.7%). Correlative analysis between risk factors and SMI revealed that higher number of was associated with not only more positive TMT and AEM test along with increased episodes of SMI but also increased degree of ST-T depression. It was also found that AEM is more sensitive than TMT (80% Vs 48%) for diagnosing SMI (SED = 9.03%), though specificity of the tests is same (93.3%).
 ...
PMID:Risk factors and their implication on silent myocardial ischaemia. 235 99

The relationship between preinfarction clinical status and short-term outcome was prospectively evaluated in 775 patients hospitalized with acute myocardial infarction after reperfusion therapy. It was anticipated that a history of angina preceding myocardial infarction by more than 7 days would be associated with more extensive underlying coronary artery disease and a more complicated in-hospital course. However, although this group did have a higher risk profile for coronary artery disease (hypertension 53.6% vs 37.2%; diabetes 22.5% vs 12.1%; hyperlipidemia 19.4% vs 9.8%; mean number of risk factors 2.2 vs 1.7, p = 0.0001), a higher incidence of multivessel disease (57.7% vs 39.6%, p less than 0.0001), worse baseline global left ventricular function (left ventricular ejection fraction 48.8% vs 51.3%, p = 0.03), and impaired function of the noninfarct zone (-0.05 vs +0.46 SD/chord, p = 0.002), the in-hospital course was less complicated than in the group without prior angina. Patients without antecedent angina had a higher rate of reocclusion of the infarct-related artery (13.6% vs 8.2%; p = 0.048). Although the difference did not reach statistical significance (7.2% vs 4.6%; p = 0.21), the in-hospital mortality rate was also higher in this group. These findings suggest that a history of prior angina is not necessarily associated with an unfavorable short-term prognosis after reperfusion therapy. This may be related to the greater prior use by this group of beta-adrenergic- and calcium channel-blocking agents (23.1% vs 8.5% and 20.7% vs 3.8%, respectively). It may also be related to the beneficial effects of collateral vessels, myocardial preconditioning, or differences in the native fibrinolytic system.
 ...
PMID:Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 240 8

Vascular risk, mainly thromboembolitic risk, attributed to oral contraceptives (OCs) since 1962, has been primarily linked to ethinyl estradiol (EE). OCs which combine estrogen and have been associated with cerebral vascular accidents. A 1977 study showed a 40% increase of mortality due to cardiovascular complications in women taking OCs. There were of both an arterial and a venous character. The risk of myocardial infarction was 3 times more frequent among OC users. Deep venous thrombosis and pulmonary embolism were more numerous. Some other risk factors include smoking, hypertension, diabetes, and age 35. The risk of heart attack vanishes a few years after stopping OC use. The reduction of EE (and similarly progesterone) dosage from 100-50 mcg also lower the risk of hypertension, cerebral vascular accidents, and venous thrombosis. Prolonged use of OCs causes disorders of hemostasis affecting the walls of blood vessels, modifying the viscosity of blood flow (increase of hematocrits, reduction of venous tonus), modifying plasmatic coagulation (increase of platelets, increase of factors VII and X and plasma fibrinogen, and decrease of antithrombin III activity), and increased fibrinolysis. These anomalies are exclusively associated with high doses of estrogens. 5% of women using OCs develop moderate hypertension of 5-10 mm Hg of systolic pressure 5 years later, but after cessation it is reversed. OCs stimulate the renin-angiotensin-aldosterone system causing accelerated production of angiotensin II with the resultant forceful vasotension. 3 months after quitting OC use, high blood pressure returns to normal. EE can provoke diabetes; it increases very low density lipoprotein (VLDL) and high density lipoprotein (HDL) production, but total cholesterol is hardly affected. The androgenic property of progestogens reduces HDL. Combined OCs are contraindicated for women with hypertension, hyperlipidemia, diabetes, and a family history of vascular accidents.
 ...
PMID:[Oral contraception and the vascular risk]. 251 20

Treatment of hypertension aims at preventing strokes and coronary events. Although diuretics and beta-blockers lowered blood pressure effectively and allowed prevention of strokes in large-scale trials, they did not reduce the incidence of myocardial infarction or coronary death. The failure of diuretics and beta-blockers to afford cardiac protection may be due in part to the unfavourable effects of these agents on associated risk factors like hyperlipidaemia and smoking. Hyperlipidaemia is more prevalent in hypertensive patients than in matched normotensive controls, and the combination of hyperlipidaemia and smoking is more frequent than can be expected to occur by chance. Diuretics and beta-blockers affect lipid metabolism negatively. Unlike these agents, alpha-blockers do not alter serum lipids and might reduce triglyceride and cholesterol levels. Several trials have shown that the outcome of treatment with beta-blockers was less favourable in smokers than in non-smokers in terms of blood pressure control and prevention of coronary events. A possible explanation is provided by acute experiments in which beta-blockade enhanced the systemic and coronary vasoconstriction elicited by smoking, while alpha-blockade had the opposite effect. Although there is reason to believe that alpha-blockers may be preferable to diuretics and beta-blockers for the treatment of high risk hypertensive patients who smoke and/or exhibit high levels of serum lipids, there is a need for larger and longer trials to test their ability to reduce cardiovascular risk.
 ...
PMID:Interactions between antihypertensive agents, serum lipids and cigarette smoking in high risk hypertensive patients. 257 76


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>